Cargando…

Minimal residual disease monitoring in acute myeloid leukemia with non-A/B/D NPM1 mutations by digital polymerase chain reaction: feasibility and clinical use

Detalles Bibliográficos
Autores principales:	Lesieur, Auriane, Thomas, Xavier, Nibourel, Olivier, Boissel, Nicolas, Fenwarth, Laurène, De Botton, Stéphane, Fournier, Elise, Celli-Lebras, Karine, Raffoux, Emmanuel, Recher, Christian, Lambert, Juliette, Berthon, Céline, Pigneux, Arnaud, Itzykson, Raphael, Turlure, Pascal, Pautas, Cécile, Vargaftig, Jacques, Preudhomme, Claude, Dombret, Hervé, Duployez, Nicolas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2020
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8168487/ https://www.ncbi.nlm.nih.gov/pubmed/33299234 http://dx.doi.org/10.3324/haematol.2020.260133

Ejemplares similares

Clofarabine Improves Relapse-Free Survival of Acute Myeloid Leukemia in Younger Adults with Micro-Complex Karyotype
por: Fenwarth, Laurène, et al.
Publicado: (2019)

LSC17 score complements genetics and measurable residual disease in acute myeloid leukemia: an ALFA study
por: Vasseur, Loïc, et al.
Publicado: (2023)

Early detection of WT1 measurable residual disease identifies high-risk patients, independent of transplantation in AML
por: Lambert, Juliette, et al.
Publicado: (2021)

Frugal alignment-free identification of FLT3-internal tandem duplications with FiLT3r
por: Boudry, Augustin, et al.
Publicado: (2022)

Publisher Correction: Frugal alignment-free identification of FLT3-internal tandem duplications with FiLT3r
por: Boudry, Augustin, et al.
Publicado: (2022)

Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment
por: Fenwarth, Laurène, et al.
Publicado: (2020)

UBTF tandem duplications define a distinct subtype of adult de novo acute myeloid leukemia
por: Duployez, Nicolas, et al.
Publicado: (2023)

MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin
por: Lambert, Juliette, et al.
Publicado: (2014)

Hematopoietic differentiation at single-cell resolution in NPM1-mutated AML
por: Duchmann, Matthieu, et al.
Publicado: (2022)

Hereditary Predisposition to Acute Myeloid Leukemia in Older Adults
por: Fenwarth, Laurène, et al.
Publicado: (2021)

Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: Results of the ALFA-0701 trial
por: Renneville, Aline, et al.
Publicado: (2014)

Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group
por: Ferret, Yann, et al.
Publicado: (2018)

Relative Mitochondrial Priming Predicts Survival in Older AML Patients Treated Intensively
por: Dal Bello, Reinaldo, et al.
Publicado: (2022)

SNP-array lesions in core binding factor acute myeloid leukemia
por: Duployez, Nicolas, et al.
Publicado: (2018)

Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial
por: Lambert, Juliette, et al.
Publicado: (2019)

Biological Effects of BET Inhibition by OTX015 (MK-8628) and JQ1 in NPM1-Mutated (NPM1c) Acute Myeloid Leukemia (AML)
por: Djamai, Hanane, et al.
Publicado: (2021)

Outcomes following hematopoietic stem cell transplantation in patients treated with standard chemotherapy with or without gemtuzumab ozogamicin for acute myeloid leukemia
por: Pautas, Cécile, et al.
Publicado: (2021)

Efficacy of Tyrosine Kinase Inhibitor Therapy in a Chemotherapy-refractory B-cell Precursor Acute Lymphoblastic Leukemia With ZC3HAV1-ABL2 Fusion
por: Decool, Gauthier, et al.
Publicado: (2019)

Benefits of dexamethasone on early outcomes in patients with acute myeloid leukemia with hyperleukocytosis: a propensity score matched analysis
por: Cerrano, Marco, et al.
Publicado: (2023)

Clinical Significance of ABCB1 in Acute Myeloid Leukemia: A Comprehensive Study
por: Boyer, Thomas, et al.
Publicado: (2019)

A 17-gene-expression profile to improve prognosis prediction in childhood acute myeloid leukemia
por: Duployez, Nicolas, et al.
Publicado: (2018)

Germline pathogenic variants in transcription factors predisposing to pediatric acute myeloid leukemia: results from the French ELAM02 trial
por: Fenwarth, Laurène, et al.
Publicado: (2020)

IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association
por: Debarri, Houria, et al.
Publicado: (2015)

The Impact of DNMT3A Status on NPM1 MRD Predictive Value and Survival in Elderly AML Patients Treated Intensively
por: Heiblig, Maël, et al.
Publicado: (2021)

Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group
por: Adès, Lionel, et al.
Publicado: (2018)

Actinomycin D Targets NPM1c-Primed Mitochondria to Restore PML-Driven Senescence in AML Therapy
por: Wu, Hsin-Chieh, et al.
Publicado: (2021)

A multiparametric niche-like drug screening platform in acute myeloid leukemia
por: Dal Bello, Reinaldo, et al.
Publicado: (2022)

Post-remission outcomes in AML patients with high hyperleukocytosis and inaugural life-threatening complications
por: Fodil, Sofiane, et al.
Publicado: (2022)

Next-generation sequencing of FLT3 internal tandem duplications for minimal residual disease monitoring in acute myeloid leukemia
por: Bibault, Jean-Emmanuel, et al.
Publicado: (2015)

Determining the contribution of NPM1 heterozygosity to NPM-ALK-induced lymphomagenesis
por: McDuff, Fiona Kate Elizabeth, et al.
Publicado: (2011)

Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome
por: Raffoux, Emmanuel, et al.
Publicado: (2010)

Characteristics and clinical outcomes of SARS-CoV-2 infection in adult patients with acute leukemia in France
por: Dumas, Pierre-Yves, et al.
Publicado: (2022)

Diagnosis of intrachromosomal amplification of chromosome 21 (iAMP21) by molecular cytogenetics in pediatric acute lymphoblastic leukemia
por: Duployez, Nicolas, et al.
Publicado: (2015)

Function of homo- and hetero-oligomers of human nucleoplasmin/nucleophosmin family proteins NPM1, NPM2 and NPM3 during sperm chromatin remodeling
por: Okuwaki, Mitsuru, et al.
Publicado: (2012)

Allogeneic transplantation in acute myelogenous leukemia: a comprehensive single institution's experience
por: Socie, Gerard, et al.
Publicado: (2023)

Characterization and dynamics of specific T cells against nucleophosmin-1 (NPM1)-mutated peptides in patients with NPM1-mutated acute myeloid leukemia
por: Forghieri, Fabio, et al.
Publicado: (2019)

NPM and NPM-MLF1 interact with chromatin remodeling complexes and influence their recruitment to specific genes
por: Darracq, Anaïs, et al.
Publicado: (2019)

BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells
por: Coudé, Marie-Magdelaine, et al.
Publicado: (2015)

Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis
por: de Botton, Stéphane, et al.
Publicado: (2021)

A transcriptomic continuum of differentiation arrest identifies myeloid interface acute leukemias with poor prognosis
por: Bond, Jonathan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1qd4cgn5jebq27gssf7jvol081